Serevent, Advair, Foradil Relegated To Second-Line For Asthma Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Public Health Advisory says long-acting beta agonist bronchodilators “should be added to the asthma treatment plan only if other medicines do not control asthma.”
You may also be interested in...
Dey Perforomist Inhalation Solution Clears FDA for Bronchoconstriction In COPD
Approval marks the first FDA-approved nebulizer formulation of formoterol.
Dey Perforomist Inhalation Solution Clears FDA for Bronchoconstriction In COPD
Approval marks the first FDA-approved nebulizer formulation of formoterol.
GSK/Theravance Target 2008 Phase III Start For Next-Gen Bronchodilators
Two compounds stemming from the collaboration given once daily were equivalent to salmeterol twice daily in Phase IIb clinical studies.